DALLAS--(BUSINESS WIRE)--CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their diabetes. In addition to improved clinical outcomes, health plans and risk-bearing providers can also realize savings of up to $2,200 per patient per year from this increase in CGM adherence and better glycemic control.
With the deployment of this new predictive model, PropheSee, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups.* The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification, along with the timely delivery of patient-specific information and insights that support long-term therapy adherence.
CCS’ dataset — which includes decades of deep, proprietary patient behavior data — paints a significantly more holistic picture of an individual’s health and well-being versus claims data, which is often delayed and not fully reflective of their journey. Also of note, patient-level Social Determinants of Health (SDOH) data and insights round out a more comprehensive view of each patient and empower healthcare organizations to proactively identify those most at risk of falling off therapy.
“CCS can now proactively identify if a member is at a higher risk of falling off therapy, and then take action based on individual specific insights to best support them in maintaining adherence,” said Richard Mackey, CTO at CCS. “The launch of PropheSee reinforces our commitment at CCS to deliver a smarter, more personalized approach to keeping people on therapy — resulting in healthier members and lower cost for the healthcare ecosystem.”
Chinmoy Barua, Managing Director of Data & AI at Accenture, added, “The innovative, advanced analytics predictive model that Accenture collaborated with CCS to develop will help identify patients at risk of non-adherence to diabetic treatment up to 90 days in advance. Taking real-time, personalized action, the tool intends to drive better adherence and improved outcomes. Trusted studies suggest that better engagement with patients leads to better health outcomes and overall quality of life.”
To learn more about how CCS’ chronic care management platform and AI-powered predictive model, PropheSee, can help your healthcare organization improve outcomes and reduce total costs of care for members living with diabetes, please visit: https://ccsmed.com/predictive-analytics/.
*Ongoing A/B testing among CCS customers conducted demonstrates increases by as much as 50% in re-order authorizations.
About CCS
CCS is a leading chronic care management company, providing clinical solutions and home-delivered medical supplies for those living with chronic conditions, particularly diabetes. The company works specifically with health plans, providers, and employers to defragment the patient journey by combining all of the following into one seamless platform experience: medical devices, pharmaceuticals and clinical education and coaching services. To holistically support individuals living with diabetes, CCS has advanced its AI-based machine learning and large language models to support the identification and timely engagement of high-risk members before serious adherence issues arise. CCS supports 180,000+ people living in the United States and delivers more than 1.2 million orders directly to their homes each year. After serving individuals for 30 years, CCS has the relationships, experience, and data in place to create a new era of home-based, proactive chronic care management. To learn more about CCS, please visit: CCSMed.com; LinkedIn.
